An NCI-designated Comprehensive Cancer Center

Alex Herrera, M.D.

Hematologist - Oncologist
Clinical Expertise
Research Focus
  • Immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams

Alex Herrera, M.D., earned his undergraduate degree summa cum laude from Princeton University and received his medical degree from Harvard Medical School in Boston. Dr. Herrera completed his residency in internal medicine at the Brigham and Women’s Hospital, before pursuing a hematology-oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital. Dr. Herrera is the Toni and Emmet Stephenson Leukemia & Lymphoma Society Scholar in Clinical Research.
Dr. Herrera's clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma. He leads several clinical trials evaluating immune checkpoint inhibitors and other novel agents for the treatment of relapsed or refractory non-Hodgkin lymphoma or classical Hodgkin lymphoma and in lymphoma patients undergoing hematopoietic stem cell transplantation. He also studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation, including immunohistochemical and cytogenetic biomarkers and sequencing-based circulating tumor DNA detection, as well as gene expression, mutational profiling, and quantitative spatial immunofluorescence of tumor cells and the tumor microenvironment to identify biomarkers predictive of response to a treatment. The goal of these studies is to identify target populations for enrollment in rational prospective clinical trials using biomarker-based interventions to improve outcomes.
Dr. Herrera is the recipient of several honors, grants and awards, including the Toni and Emmet Stephenson Leukemia & Lymphoma Society Scholar in Clinical Research Award, American Society of Blood and Marrow Transplantation/Biology of Blood and Marrow Transplantation George Santos Award for Best Clinical Science Article by a New Investigator, American Society of Clinical Oncology/Conquer Cancer Foundation Young Investigator Award, City of Hope K12 Paul Calabresi Career Development Award for Clinical Oncology, and the Lymphoma Research Foundation Larry and Denise Mason Clinical Investigator Career Development Award. He has published over 40 peer-reviewed publications and book chapters, and has been invited to present his work nationally and internationally. Dr. Herrera is a member of several national and international guidelines committees including the NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma, the SWOG Lymphoma Committee Working Group, the CIBMTR Committee on Practice Guidelines, and he is a Co-Chair of the CIBMTR Lymphoma Working Committee.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Song JY, Egan C, Bouska AC, Zhang W, Gong Q, Venkataraman G, Herrera AF, Chen L, Ottesen R, Niland JC, Bedell V, Valle-Catuna M, Murata-Collins J, Weisenburger DD, Iqbal J, Jaffe ES, Chan WC. Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. Leukemia. 2020 Feb 13. doi: 10.1038/s41375-020-0739-7. [Epub ahead of print] PMID: 32054999
  • Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 Jan 14;4(1):122-126. doi: 10.1182/bloodadvances.2019000784. PMID: 31917843
  • Chen R, *Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman SJ, Kwak LW, Rosen ST, Newman EM. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clin Cancer Res. 2019 Dec 6. doi: 10.1158/1078-0432.CCR-19-1768. [Epub ahead of print] PMID: 31811017
*These authors contributed equally
  • Herrera AF. Highlights in Lymphoma From the 60th American Society of Hematology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2019 Feb;17 Suppl 4(2):20-23. PMID: 31730577
  • Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165. doi: 10.1200/JCO.19.00172. Epub 2019 Nov 6. PMID: 31693429
  • Herrera AF, Goy A, Mehta A, Ramchandren R, Pagel JM, Svoboda J, Guan S, Hill JS, Kwei K, Liu EA, Phillips T. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. Am J Hematol. 2020 Jan;95(1):18-27. doi: 10.1002/ajh.25659. Epub 2019 Nov 6 PMID: 31621094
  • Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Chen YB, Armand P, Shadman M. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. Biol Blood Marrow Transplant. 2019 Dec;25(12):2383-2387. 2019 Aug 5. pii: S1083-8791(19)30513-0. doi: 10.1016/j.bbmt.2019.07.041. [Epub ahead of print]. PMID: 31394277
  • Herrera AF. Noncellular Immune Therapies for Non-Hodgkin Lymphoma. Hematol Oncol Clin North Am. 2019 Aug;33(4):707-725. doi: 10.1016/j.hoc.2019.03.007. Epub 2019 May 11. Review. PMID: 31229164
  • Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Lower GVHD and relapse risk in PTCy-based Haploidentical vs Matched Sibling Donor RIC Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2019 May 24. pii: S1083-8791(19)30336-2. doi: 10.1016/j.bbmt.2019.05.025. [Epub ahead of print] PMID: 31132455
  • Moskowitz AJ, Herrera AF, Beaven AW. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy. Am Soc Clin Oncol Educ Book. 2019 Jan;39:477-486. doi: 10.1200/EDBK_238799. Epub 2019 May 17. PMID: 31099645
  • Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol. 2019 May 1. doi: 10.1111/bjh.15923. [Epub ahead of print]. PMID: 31044423
  • Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood. 2019 Apr 5. pii: blood.2019000215. doi: 10.1182/blood.2019000215. [Epub ahead of print]. PMID: 30952672
In The News
An Expert's Voice
T cell therapy

New Immunotherapy Research Presented at ASH

breakthroughs - t cells

New Immunotherapy Research Presented at ASH Annual Meeting 2019

T cell therapy

New immunotherapies detailed at ASH conference